Last reviewed · How we verify
SHP655
At a glance
| Generic name | SHP655 |
|---|---|
| Also known as | rADAMTS-13 |
| Sponsor | Shire |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP) (PHASE2)
- A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP) (PHASE3)
- A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura (PHASE3)
- A Study of SHP655 (rADAMTS13) in Sickle Cell Disease (PHASE1)
- Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SHP655 CI brief — competitive landscape report
- SHP655 updates RSS · CI watch RSS
- Shire portfolio CI